Pharmacogenetics of Crohn's disease (Q37205946)

18 August 2017

1 reference

title

Pharmacogenetics of Crohn's disease (English)

1 reference

18 August 2017

0 references

Helga-Paula Török

1

1 reference

18 August 2017

Burkhard Göke

series ordinal

2

1 reference

18 August 2017

Astrid Konrad

series ordinal

3

1 reference

18 August 2017

publication date

1 July 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

7

1 reference

18 August 2017

page(s)

881-893

1 reference

What's new in inflammatory bowel disease in 2008?

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Treatment of inflammatory bowel disease with corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Pharmacogenomics and individualized drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

MDR1 gene: susceptibility in Spanish Crohn's disease and ulcerative colitis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Absence of association between the multidrug resistance (MDR1) gene and inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Effects of azathioprine and its metabolites on repair mechanisms of the intestinal epithelium in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

TPMT in the treatment of Crohn's disease with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Small bowel malignancy at diagnosis of coeliac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Use of methotrexate in refractory Crohn's disease: the Edinburgh experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Molecular action of methotrexate in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

The pharmacogenetics of methotrexate in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

The pharmacogenetics of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Tacrolimus: the drug for the turn of the millennium?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Clinical aspects of the MDR1 (ABCB1) gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Predictors of response to infliximab in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Lack of common NOD2 variants in Japanese patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Anti-interleukin-12 antibody for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Interleukin-23 drives innate and T cell-mediated intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Sargramostim for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Defective acute inflammation in Crohn's disease: a clinical investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Crohn's disease is associated with a toll-like receptor-9 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Diagnostics of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and Inflammatory Bowel Disease and their effects on disease behavior: A case-control and meta-analysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

NOD2/CARD15 does not influence response to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Lymphotoxin alpha gene in Crohnʼs disease patients: absence of implication in the response to infliximab in a large cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohnʼs disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Polymorphisms of Tumor Necrosis Factor-α but Not MDR1 Influence Response to Medical Therapy in Pediatric-Onset Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.7.881

21 January 2018

Identifiers

DOI

10.2217/14622416.9.7.881

1 reference

release_36j63ruxv5findu35v2afy6vay

18 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/36j63ruxv5findu35v2afy6vay

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference